Adial Pharmaceuticals, Inc.: adjourns vote on four proposals

What happened Adial Pharmaceuticals, Inc. filed an 8-K on Oct 2, 2026 reporting that it adjourned the vote on Proposals 3, 4, 5 and 6 of its 2026 Annual Meeting. The company previously convened the meeting on Sep 17, 2026, moved forward with votes on Proposals 1, 2, 7, 8, 9, 10, 11 and 12, and adjourned Proposals 3–6 to Oct 1, 2026. On Oct 1, 2026 the company reconvened the meeting for Proposals 3–6 but further adjourned those proposals because it had not received Nasdaq’s approval of the Initial Listing Application; the adjourned meeting will reconvene on Oct 15, 2026 at 8:30 a.m. Eastern Time at the company’s offices.

Key details

• Proposals adjourned: Proposals 3, 4, 5 and 6; polls remain open for those proposals.
• Reconvene date/time/location: Oct 15, 2026 at 8:30 a.m. Eastern Time at 650 Peter Jefferson Parkway, Suite 230, Charlottesville, Virginia 22911.
• Record date: Aug 17, 2026 remains the record date for the 2026 Annual Meeting.
• Proxy and filings: Definitive proxy statement was filed with the SEC on Aug 24, 2026; stockholders who already submitted proxies on Proposals 3–6 do not need to take further action unless they wish to change their vote.

Why it may matter This 8-K reports Item 8.01 (Other events) and covers the adjournment and reconvening details for the 2026 Annual Meeting and the related proxy solicitation due to the pending Nasdaq Initial Listing Application.

This filing does not show why the insider traded or why the company acted.